WGS Q4 2022 Earnings — GeneDx Holdings Corp. Revenue & Financial Results | Market Cap Arena

WGSGeneDx Holdings Corp.

$3B

Q4 2022 Earnings

Healthcare Medical - Healthcare Information Services

Income Statement

Revenue

$61M+6.1% YoY

Gross Profit

-$16M-26.6% margin

Operating Income

-$325M-529.6% margin

Net Income

-$309M-503.3% margin

EPS (Diluted)

$-26.23

QoQ Revenue Growth

-26.3%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$67M

Stock-Based Comp.

$422,000

Balance Sheet

Total Assets

$545M

Total Liabilities

$292M

Stockholders' Equity

$254M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$61M	$58M	+6.1%
Gross Profit	-$16M	$9M	-277.5%
Operating Income	-$325M	-$116M	-180.0%
Net Income	-$309M	-$40M	-663.7%

Revenue Segments

Diagnostic Test

$59M49%

Diagnostic Test, Third Party Insurance

$40M33%

Diagnostic Test, Institutional Customers

$16M13%

Diagnostic Test, Self Pay

$3M3%

Product and Service, Other

$2M2%